Business Context and Reporting Period
This Form 8-K is a current report filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on December 4, 2020, regarding an event that occurred on December 2, 2020. The company is a Delaware corporation with its principal executive offices in Boulder, Colorado, and its common stock trades on the Nasdaq Stock Market under the symbol MGEN.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial figures disclosed relate to executive compensation and severance benefits:
- Target Bonus: $166,000 (100% of 2020 target bonus for the departing officer).
- Severance Salary: 12 months of current base salary.
- Equity: Accelerated vesting of all currently unvested and outstanding stock options.
- Benefits: COBRA premium coverage for up to 12 months.
Material Changes
The material change reported is the departure of a senior executive:
- Resignation: Diana Escolar, M.D., FAAN, resigned as Chief Medical Officer, effective January 1, 2021.
- Compensatory Arrangement: The company anticipates entering into a Separation Agreement contingent upon the execution of a general release.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, outlook, or management commentary regarding business operations. The primary contingency noted is that the severance benefits are conditioned upon Dr. Escolar providing a general release in favor of the Company.
Investor Verification Checklist
- Verify the company name is Miragen Therapeutics, Inc. (MGEN), not Viridian Therapeutics.
- Confirm the effective date of the Chief Medical Officer's resignation (January 1, 2021).
- Review the final Separation Agreement to confirm the exact base salary amount used for the 12-month severance calculation.
- Check subsequent filings to confirm the execution of the general release required for the severance package.